tradingkey.logo

Merck Announces Phase 3 Keynote-B96 Trial Met Primary Endpoint Of Progression-Free Survival (Pfs) In Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed Pd-L1 And In All Comers

ReutersMay 15, 2025 11:34 AM

- Merck & Co Inc MRK.N:

  • MERCK ANNOUNCES PHASE 3 KEYNOTE-B96 TRIAL MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER WHOSE TUMORS EXPRESSED PD-L1 AND IN ALL COMERS

  • MERCK & CO INC - STUDY MEETS SECONDARY ENDPOINT OF OVERALL SURVIVAL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI